ZBZahra Babazadeh

Zahra Babazadeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zahra Babazadeh has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Abdolreza Daraei

    Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

    2 shared publications
  • Mehdi Nikbakht Dastjerdi

    Department of Anatomical Sciences and Molecular Biology, Medical School, Isfahan University of Medical Sciences, Isfahan, Iran

    2 shared publications
  • Soraya Khafri

    Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

    2 shared publications
  • Zohre Esmaeili

    Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

    2 shared publications
  • A. Esmaeili

    Cell, Molecular and Developmental Biology Division, Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, I.R. Iran

    1 shared publication
  • AbdolReza Rostami

    Student Research Committee, Babol University of Medical Sciences, Babol, Iran

    1 shared publication

Latest Publications

  • Disulfiram attenuates paraquat-induced renal injury and fibrosis accompanied by changes in Smad3 and Smad7 gene expression

    by Mahtab Esmaeili, Abdolreza Daraei, Hossein Najafzadehvarzi, Soraya Khafri, Zohre Esmaeili, Yousef Beheshti, Zahra Babazadeh

    Purpose Paraquat (PQ) is a highly toxic herbicide that induces renal injury through oxidative stress and progressive fibrosis, contributing to chronic kidney disease. Drug repurposing offers a promising strategy for accelerating therapeutic development. This study evaluated the nephroprotective potential of disulfiram (DSF), a clinically approved drug with emerging antioxidant and antifibrotic properties, against PQ-induced renal injury, including its association with changes in the expression of the Smad3 and Smad7 genes. Methods Thirty-five male Wistar rats were randomly assigned to seven groups: Control, Vehicle, DSF20, PQ (1.5 mg/kg), and PQ co-treated with DSF (5, 10, or 20 mg/kg). Renal injury was evaluated using histopathology (H&E, PAS, and Masson’s trichrome staining), α-SMA, serum biomarkers (BUN, creatinine, and uric acid), oxidative stress parameters (malondialdehyde [MDA], catalase [CAT], and glutathione peroxidase [GPx]), and Smad3 and Smad7 gene expression determined by qRT-PCR. Results PQ exposure caused marked renal histopathological injury, increased α-SMA, increased oxidative stress, impaired renal function, and elevated fibrosis, accompanied by increased Smad3 and decreased Smad7 gene expression. DSF co-treatment, particularly at 10 mg/kg, significantly ameliorated these changes by reducing tissue injury, decreasing α-SMA-positive area% and collagen deposition, restoring antioxidant enzyme activity, lowering lipid peroxidation, improving renal function, and altering Smad3 and Smad7 gene expression toward PQ levels. Conclusion Disulfiram at an optimal dose of 10 mg/kg significantly attenuated PQ-induced renal injury and fibrosis, accompanied by reduced oxidative stress and altered Smad3 and Smad7 gene expression. These findings support the potential of DSF as a repurposed therapeutic candidate for mitigating paraquat-induced renal injury and fibrosis. Further studies evaluating protein-level changes and activation of the TGF-β/Smad signaling pathway are warranted to clarify the underlying molecular mechanisms. Graphical abstract


  • Open Access

    Design and psychometric evaluation of a short questionnaire for assessing student satisfaction with innovative teaching methods in basic medical sciences

    by Sobhan Rahimi Esbo, Maryam Ghaemi-Amiri, Zahra Babazadeh

    Basic medical sciences form the foundation for clinical competence; however, students often face difficulties in retaining theoretical knowledge due to abs

    • 13 December 2025
      • Vol. 18  (4) , 426-437
    Open Access

    Can disulfiram modulate liver injury in CCl4-induced fibrosis in rats?

    by AbdolReza Rostami, Ravieh Golchoobian, Zohre Esmaeili, Mohammad Hossein Asghari, Nasim Hafezi, Zahra Babazadeh

    This study aimed to evaluate the hepatoprotective and antifibrotic effects of DSF in a rat model of CCl4-induced liver fibrosis. Liver fibrosis is a chronic and potentially life-threatening condition characterized by fibroblast proliferation and excessive extracellular matrix deposition. Oxidative stress and inflammation are central mechanisms in its pathogenesis. Disulfiram (DSF), known for its antioxidant and potential antifibrotic properties, may attenuate liver injury. Thirty-five male Wistar rats were randomly divided into seven groups (n = 5 per group): Control, Oil, DSF 25 mg/kg, DSF 50 mg/kg, CCl4, CCl4 + DSF 25 mg/kg, and CCl4 + DSF 50 mg/kg. After seven weeks of treatment, liver histopathology, serum liver enzymes (ALT, AST, ALP), and malondialdehyde (MDA) levels were assessed. CCl4 administration significantly increased serum ALT and AST levels compared with the Control group (p < 0.001). DSF at 25 mg/kg significantly reduced ALT (p = 0.0265), AST (p = 0.0334), and MDA (p < 0.001) compared with the CCl4 group. Histopathological analysis revealed improved hepatocyte morphology in the low-dose DSF group (p = 0.0358). However, neither DSF dose produced a significant reduction in collagen deposition or vascular congestion, indicating no clear antifibrotic effect at these doses (>0.9999). Low-dose DSF demonstrated hepatoprotective effects through improvements in biochemical markers and hepatocyte morphology, but failed to significantly attenuate fibrosis. These findings suggest that lower DSF concentrations (< 25 mg/kg) may offer greater antifibrotic potential and should be further investigated in dose-response studies.

  • Repurposing disulfiram: targeting Zeb1 to attenuate paraquat-induced pulmonary fibrosis in rats

    by Fatemeh Karimzadeh, Abdolreza Daraei, Ebrahim Zabihi-Neyshaburi, Farideh Feizi, Mohammad Ranaee, Soraya Khafri, Zohre Esmaeili, Zahra Babazadeh

    Pulmonary fibrosis is a fatal condition marked by excessive extracellular matrix deposition and myofibroblast activation, with paraquat (PQ) being a potent


    • 1 January 2014
      • Vol. 9  (4) , 287-294
    Open Access

    Effects of disulfiram on apoptosis in PANC-1 human pancreatic cancer cell line

    by M. Nikbakht Dastjerdi, Z. Babazadeh, M. Rabbani, M. Gharagozloo, A. Esmaeili, M. Narimani

    Pancreatic carcinoma is currently considered as a rapidly progressive and fatal disease, and is typically diagnosed late in its natural course. It is characterized by a poor diagnosis and lack of response to conventional therapy. Recent studies have suggested that disulfiram (DSF), a member of the dithiocarbamate family, may have antitumor activity. This study aimed to evaluate the in vitro effect of DSF on apoptosis in human pancreatic cancerous cell line (PANC-1). PANC-1 cells were cultured and treated with DSF at doses of 5, 10, 13 mu M for 24 h and apoptosis was measured. Methylation specific PCR (MS-PCR) and real-time quantitative PCR were carried out to detect the methylation pattern and to estimate the mRNA expression levels of RASSF1A, p21 and Bax. MS-PCR analysis demonstrated that no unmethylated band was apeared in PANC-1 cell line after DSF treatments. The real-time quantitative PCR results showed no significant mRNA expression for RASSF1A (p>0.05); whereas p21 and Bax expression were significantly (p<0.01) enhanced after treatment with DSF. The results of the current study indicated that DSF can induce appoptosis in PANC-1 through p21 and Bax pathway but not through RASSF1A.


  • Open Access

    Lack of significance of the BRCA2 promoter methylation status in different genotypes of the MTHFR a1298c polymorphism in ovarian cancer cases in Iran.

    by Ahmad Shabanizadeh Darehdori, Mehdi Nikbakht Dastjerdi, Hajar Dahim, Mohammadreza Slahshoor, Zahra Babazadeh, Mohammad Mohsen Taghavi, Zahra Taghipour, Hamidreza Gaafarineveh

    Promoter methylation, which can be regulated by MTHFR activity, is associated with silencing of genes. In this study we evaluated the methylation status (type) of the BRCA2 promoter in ovarian cancer patients carrying different genotypes of the MTHFR gene (A or C polymorphisms at position 1298).


  • Sperm DNA damage and its relation with leukocyte DNA damage

    by Zahra Babazadeh, Shahnaz Razavi, Marziyeh Tavalaee, Mohammad Reza Deemeh, Maryam Shahidi, Mohammad Hossein Nasr-Esfahani